Sign in
4

Changes in Ownership

Prelude Therapeutics Inc Filed Acc 0001562180-23-001170

Options or other derivatives

  • Chief Scientific Officer acquired 135,000 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Table II: Derivative

Insider Date Transaction Shares Price Value Owned after D/I
Scherle Peggy Chief Scientific Officer 2023-02-07 Grant or award · Employee Stock Option (right to buy) +135,000 135,000 D: show line 1 in the form
Loading xslF345X03/primarydocument.xml…